Omuro et al. conducted CheckMate 498 for newly diagnosed supratentorial GBM with MGMT promoter unmethylation in 2022 [20] and evaluated the efficacy of concurrent radiotherapy with Nivolumab followed by adjuvant Nivolumab by comparisons with standard STUPP regimen [71]. Here, MGMT is linked to glioblastoma.